Full steam ahead at F2G
The UK developer has the launch of what could be the first in a new class of antifungals in its sights.
Glaxo gets a Shingrix boost
But pressure is on the shingles vaccine as the consumer spin-off approaches.
Biotech catalysts on the horizon
The second quarter should bring pivotal data for Karuna and key cardiomyopathy results for Alnylam, while Ionis's eplontersen lags in amyloidosis.
Biohaven’s high-risk bet
There are long shots and then there is troriluzole. Biohaven will soon find out if it was wise to press on with the asset.
Biotech’s important first-quarter data
Kodiak, Biomarin and Argenx prepare for clinical catalysts.
Global pharma stocks struggle in the third quarter
A strong performance from a handful of large drug developers could not rescue the sector from a weak three months on the stock market.
Biotech’s key fourth-quarter data
Deciphera, Allakos and Uniqure are all set for important data disclosures.